Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : N::A tags : Cancer save search
RSNA and GE HealthCare Bring Advanced Mammography Technology to Tanzania to Improve Access and Help Address Breast Cancer Mortality Rate
Published: 2024-04-16 (Crawled : 12:00) - prnewswire.com
GEHC | $84.47 -0.59% -0.59% 1.9M
|
n/a
|
| O: -1.94%
H: 0.71%
C: 0.06%
breast cancer technology advanced
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
APLM | $0.472 -7.45% -8.05% 170K
|
n/a
|
| O: -2.99%
H: 6.9%
C: 0.0%
association cancer research for meeting
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: -3.82%
H: 0.0%
C: -13.49%
mdna113 association cancer research preclinical for meeting
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Published: 2024-04-08 (Crawled : 10:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 0.0%
H: 1.76%
C: -0.62%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.94%
H: 1.12%
C: 0.61%
association cancer research preclinical for meeting
CYduct Diagnostics Announces Positive Study Results for Biomarker Combinations in the Assessment of Breast Cancer
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
CYDX | $0.41 -14.15% 290
|
n/a
| Email alert
Add to watchlist
breast biomarker positive cancer diagnostics results study
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
APLM | $0.472 -7.45% -8.05% 170K
|
n/a
|
| O: 5.51%
H: 0.0%
C: -5.08%
association cancer research meeting
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Published: 2024-03-27 (Crawled : 12:30) - globenewswire.com
ALLR | $1.42 -7.79% -8.45% 460K
|
n/a
|
| O: 0.32%
H: 2.87%
C: 2.87%
approval cancer therapeutics advanced
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
LUDG | $0.23 -85.29% 25K
|
n/a
|
| O: 0.0%
H: 0.0%
C: 0.0%
intelligence cancer diagnostics market
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Published: 2024-03-06 (Crawled : 12:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 3.0%
H: 6.12%
C: 0.36%
mdna11 association update cancer research meeting trial
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 1.0%
H: 3.14%
C: 1.07%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.54%
H: 0.46%
C: -1.09%
association cancer research preclinical meeting
Europe Cancer Diagnostics Market Sees Promising Growth Amid Rising Demand for Precision Diagnostics - Forecasts to 2031
Published: 2024-03-01 (Crawled : 00:20) - prnewswire.com
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
| Email alert
Add to watchlist
QGEN | $40.0 1.34% 0.0% 1.1M
|
Health Technology
| Email alert
Add to watchlist
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
| Email alert
Add to watchlist
CAJFF | $29.0664 -28.15% 760
|
Electronic Technology
| Email alert
Add to watchlist
CAJPY | $28.42 -0.41% 29K
|
n/a
| Email alert
Add to watchlist
HOLX | $75.37 0.36% 0.36% 1.3M
|
Health Technology
| Email alert
Add to watchlist
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
| Email alert
Add to watchlist
europe precision cancer diagnostics growth market
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-02-26 (Crawled : 11:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
lung chmp positive cancer cell treatment
Ludwig Enterprises mRNA Bladder Cancer Study to be Launched
Published: 2024-01-31 (Crawled : 15:00) - biospace.com/
LUDG | $0.23 -85.29% 25K
|
n/a
|
| O: -49.15%
H: 92.0%
C: 92.0%
mrna bladder cancer study
BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer
Published: 2024-01-16 (Crawled : 13:00) - globenewswire.com
BFRG | $2.71 -10.27% -11.44% 130K
|
n/a
|
| O: -0.39%
H: 5.88%
C: 3.53%
patent cancer
Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
Published: 2023-12-18 (Crawled : 14:00) - globenewswire.com
THER | $0.001 62.5% 120K
|
n/a
|
| O: 0.0%
H: 7.14%
C: -14.29%
breast cancer theralink response therapy study
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
Published: 2023-12-13 (Crawled : 21:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.91%
H: 2.03%
C: 1.4%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.11%
H: 0.5%
C: -1.78%
fda lung review cancer cell application grants advanced
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.83%
H: 1.11%
C: -0.1%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.32%
H: 0.78%
C: -1.13%
breast cancer pharmaceuticals sabcs potential
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
Published: 2023-12-05 (Crawled : 12:30) - globenewswire.com
ALLR | $1.42 -7.79% -8.45% 460K
|
n/a
|
| O: 66.69%
H: 11.0%
C: -42.04%
drp diagnostic cancer women companion advanced phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
SIX | $23.45 -0.55% 0.68% 650K
|
Consumer Services
KNSL 4 | $451.81 -0.02% 0.49% 140K
|
Finance
SENS | $0.3992 -4.04% 0.45% 2M
|
Electronic Technology
BSBR | $5.25 2.54% 0.38% 430K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.